https://doi.org/10.55788/632d772f
“Although dye-based HD-CE is considered the gold standard for detecting colorectal neoplasia in patients with IBD, the uptake remains fairly low in clinical practice, likely due to issues of practicality, cost, and training,” said Dr Maarten te Groen (Radboudumc, the Netherlands) [1]. “Therefore, HD-WLE is more frequently used in clinical practice.” He explained that it remains unknown whether the advantage of HD-CE comes from enhanced contrast or from longer withdrawal times. Evidence in the non-IBD population indicates that longer withdrawal times are correlated with higher colorectal neoplasia detection rates [2]. “We hypothesised that HD-WLE with matched withdrawal times may yield similar neoplasia detection rates as HD-CE,” Dr te Groen expressed [1].
The randomised-controlled HELIOS trial (NCT04291976) compared 3 endoscopy techniques for the outcome measure of colorectal neoplasia in patients with IBD. HD-WLE with SR was tested against HD-CE for non-inferiority and compared with single-pass HD-WLE for superiority. The trial randomised 666 adult patients with IBD who were scheduled for endoscopic surveillance 2:2:1 to HD-WLE with SR, HD-CE, or single-pass HD-WLE.
The colorectal neoplasia detection rate was 10.3% in the HD-WLE with SR arm and 13.1% in the HD-CE arm. The lower bound of the 95% confidence interval (-7.8%) did not cross the non-inferiority border of -10.0%; therefore, non-inferiority of HD-WLE with SR to HD-CE was demonstrated in this population (Pnon-inferiority<0.01). The colorectal neoplasia detection rate was 6.1% in the single-pass HD-WLE arm; the difference of 4.1% with the HD-WLE with SR arm was not statistically significant (95% CI -2.2 to 9.6%; P=0.19). Finally, the median withdrawal times were 19, 26, and 15 minutes in the HD-WLE with SR, HD-CE, and single-pass HD-WLE arms, respectively.
“HD-WLE with SR is non-inferior to HD-CE but not superior to single-pass HD-WLE,” concluded Dr te Groen. He argued that the lower-than-expected colorectal neoplasia rates and subsequent lower power of the trial could be an explanation for the result of the superiority analysis. “Also, the results indicate that the benefit from HD-CE is mostly explained by the longer withdrawal time and not necessarily by enhanced contrast.”
- Te Groen M, et al. High-definition white light endoscopy with segmental re-inspection is non-inferior to dye-based chromoendoscopy in inflammatory bowel disease: the randomized controlled HELIOS trial. OP15, 19th Congress of ECCO, 21–24 February 2024, Stockholm, Sweden.
- Shaukat A, et al. Gastroenterology. 2015;149(4):952-957.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease Next Article
Clear case for NUDT15 genetic testing in Asian patients with IBD »
« CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease Next Article
Clear case for NUDT15 genetic testing in Asian patients with IBD »
Table of Contents: ECCO 2024
Featured articles
Meet the Trialist: Dr Yasuharu Maeda on AI-assisted endoscopy
IL-23 Inhibitors on the Rise
VIVID-1: Mirikizumab meets expectations in Crohn’s disease
COMMAND: Long-term efficacy benefits of risankizumab in ulcerative colitis
SEQUENCE: Risankizumab versus ustekinumab across endpoints
QUASAR: Guselkumab improves QoL for patients with ulcerative colitis
Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease
Inspiring Drug Trials and Treatment Strategies
Novel agent VTX002 holds promise in ulcerative colitis
PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease
Biologicals and JAK inhibitors hold promise in microscopic colitis
Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease
How effective is dose escalation of biologicals in IBD?
Make Way for JAK Inhibitors
Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial
U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease
TRIUMPH: Tofacitinib as rescue option for acute severe ulcerative colitis
Focus on Endoscopy, Screening, and Risk Factors
Should we screen for metabolic bone disease at IBD diagnosis?
Predicting relapse in ulcerative colitis with AI-assisted endoscopy
Clear case for NUDT15 genetic testing in Asian patients with IBD
HELIOS: HD-WLE can yield similar neoplasia detection rates as HD-CE
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease
Sharp Surgical Solutions
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?
Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis
Risk factors for re-resection in Crohn’s disease revealed
ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula
Related Articles
August 26, 2021
Early infliximab could change the course of Crohn’s disease
May 9, 2019
Moving towards new therapeutic options
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy